Brevan Howard Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Brevan Howard Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,181	Closed	-$204K	–	2035
2026 Q1	$204K	Sell	9,181 -25,010	-73%	-$598K	﹤0.01%	1886
2025 Q4	$913K	Sell	34,191 -801	-2%	-$19.1K	0.01%	810
2025 Q3	$747K	Buy	+34,992	New	+$828K	﹤0.01%	1057
2025 Q1	–	Sell	-56,749	Closed	-$1.04M	–	1123
2024 Q4	$1.04M	Buy	56,749 +43,270	+321%	+$698K	0.01%	422
2024 Q3	$207K	Sell	13,479 -19,857	-60%	-$331K	﹤0.01%	985
2024 Q2	$542K	Sell	33,336 -513	-2%	-$8.28K	﹤0.01%	580
2024 Q1	$626K	Buy	33,849 +16,039	+90%	+$397K	0.01%	386
2023 Q4	$558K	Buy	+17,810	New	+$425K	0.01%	432

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brevan Howard Capital Management's ACAD Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 9,181 shares — an estimated $204K sold.

Brevan Howard Capital Management first reported a position in ACAD in Q4 2023 and held it in 8 quarters. The position peaked at $1.04M in Q4 2024. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Brevan Howard Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 9,181 Acadia Pharmaceuticals shares in Q2 2026, an estimated $204K.
Brevan Howard Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Brevan Howard Capital Management's Acadia Pharmaceuticals position peaked at $1.04M in Q4 2024.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.